# REP 2139-Ca / Pegasys™ Combination Therapy in Hepatitis B / Hepatitis D Co-infection

> **NCT02233075** · PHASE2 · COMPLETED · sponsor: **Replicor Inc.** · enrollment: 12 (actual)

## Conditions studied

- Chronic HBV Infection (HBeAg Negative)

## Interventions

- **DRUG:** REP 2139-Ca + Pegasys (TM)

## Key facts

- **NCT ID:** NCT02233075
- **Lead sponsor:** Replicor Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-09
- **Primary completion:** 2016-11
- **Final completion:** 2017-05
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2017-09-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02233075

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02233075, "REP 2139-Ca / Pegasys™ Combination Therapy in Hepatitis B / Hepatitis D Co-infection". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02233075. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*